GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Consensus Recommendation of “Hold” by Brokerages

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have earned a consensus recommendation of “Hold” from the thirteen research firms that are presently covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $4.2273.

Several analysts have issued reports on the stock. Wall Street Zen upgraded shares of GoodRx from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Leerink Partners set a $5.00 price target on shares of GoodRx in a research report on Thursday, August 6th. Wells Fargo & Company raised their target price on GoodRx from $3.50 to $5.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. The Goldman Sachs Group restated a “neutral” rating and set a $4.00 price target on shares of GoodRx in a research report on Friday, August 7th. Finally, TD Cowen upped their price objective on shares of GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th.

GoodRx Trading Up 0.6%

Shares of GoodRx stock opened at $3.56 on Friday. GoodRx has a 1 year low of $1.77 and a 1 year high of $5.81. The company has a 50 day simple moving average of $3.11 and a two-hundred day simple moving average of $2.62. The firm has a market cap of $1.22 billion, a PE ratio of 89.02, a PEG ratio of 1.76 and a beta of 1.60. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.38 and a quick ratio of 1.38.

GoodRx (NASDAQ:GDRX) last released its earnings results on Wednesday, August 5th. The company reported $0.08 EPS for the quarter, meeting analysts’ consensus estimates of $0.08. The business had revenue of $200.41 million for the quarter, compared to analysts’ expectations of $193.23 million. GoodRx had a return on equity of 7.22% and a net margin of 2.07%.The firm’s revenue was down 1.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.09 earnings per share. Analysts expect that GoodRx will post 0.16 earnings per share for the current fiscal year.

Hedge Funds Weigh In On GoodRx

A number of institutional investors have recently bought and sold shares of the stock. Essential Partners LLC raised its position in shares of GoodRx by 375.4% during the 1st quarter. Essential Partners LLC now owns 14,304 shares of the company’s stock valued at $28,000 after purchasing an additional 11,295 shares during the period. Meridian Wealth Management LLC bought a new position in GoodRx during the fourth quarter valued at approximately $29,000. SG Americas Securities LLC purchased a new position in shares of GoodRx in the first quarter valued at $29,000. Headlands Technologies LLC purchased a new position in shares of GoodRx in the 2nd quarter worth $30,000. Finally, Krilogy Financial LLC bought a new position in shares of GoodRx in the 1st quarter valued at about $33,000. 63.77% of the stock is owned by institutional investors.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.